Johnson & Johnson’s Revenue Breakdown (2016-2021)

Download

About

This statistic covers Johnson & Johnson’s Revenue Breakdown, split across Consumers, Medical Devices, and Pharmaceutical from 2016 onwards.
Subscribe to Pro or Enterprise plans to unlock this feature.
More information
Subscribe to Pro or Enterprise plans to unlock this feature.
Contact the Analyst
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on reddit
Share on facebook
Share on twitter
Share on linkedin
Share on email

Become a smarter investor today.

Access Business Quant for as low as $19/month

Become a smarter investor today.

Access KPI Data on listed stocks for just $19/month

This statistic covers Johnson & Johnson’s Revenue Breakdown, split across Consumers, Medical Devices, and Pharmaceutical from 2016 onwards.

Johnson & Johnson generates revenue from the following segments:

  • Consumer
  • Medical Devices
  • Pharmaceutical

Johnson & Johnson’s Revenue Breakdown

Segment Q4 2019 Q4 2020 YoY Growth Revenue Share Q4 2020
Consumer $3.57 $3.62 1.40% 16.84%
Medical Devices $6.63 $5.93 -10.55% 27.58%
Pharmaceutical $10.76 $11.95 11.05% 55.58%
Total Revenue $20.96 $21.50 2.57% 100.00%

(all figures in billions, except percentages)

Johnson & Johnson’s total revenue rose from $20.96 billion in Q4 2019 to $21.50 billion in Q4 2020, marking an increase of 2.57% on a year-on-year basis. During this period, the revenue growth was driven by higher sales of medicines like Stelara, Darzalex, Imbruvica, Opsumit, and Tremfya.

Consumer

Johnson & Johnson’s Consumer segment offers a variety of products for oral care, baby care, skincare, and many other personal healthcare products. The company’s major brands include Clean & Clear, Neutrogena, Aveeno, Benadryl, Nicorette, Listerine, Stayfree, Carefree, Band-Aid, Neosporin, and many others. These products are used for the treatment of allergy, cough and cold, smoking cessation, and pain relief. Johnson & Johnson sells these products in different parts of the world through retail outlets, distributors, and e-commerce websites.

Johnson & Johnson’s revenue from the Consumer segment increased from $3.57 billion in Q4 2019 to $3.62 billion in Q4 2020, a growth of 1.40% on a year-on-year basis. In Q4 2020, the Consumer segment contributed 16.84% to the company’s total revenue. 

Medical Devices

Johnson & Johnson’s Medical Devices segment includes various types of devices used in Surgery, Interventional Solutions, Orthopaedics, and Vision Fields. 

  • Surgery: Johnson & Johnson provides solutions for ear, nose, and throat procedures, and other advance and general surgeries.
  • Interventional Solutions: The company provides medical devices for the treatment of cardiovascular diseases, hemorrhagic and ischemic stroke.
  • Orthopedics: Johnson & Johnson’s Orthopedic portfolio consists of orthopedic products for hips, trauma, knees, and spine. The company’s major brand in the orthopedic segment is Depuy Synthes.
  • Vision Fields: Johnson & Johnson Vision Fields product portfolio includes ophthalmic products for laser refractive surgery and cataract. The company’s major brand in this segment is Acuvue.

The company distributes these products to retailers and hospitals and is used by doctors, nurses, ophthalmologists, and physicians.

Johnson & Johnson’s revenue from the Medical Devices segment declined from $6.63 billion in Q4 2019 to $5.93 billion in Q4 2020, marking a decline of 10.55% on a year-on-year basis. During this period, the Medical Devices segment contributed 27.58% to Johnson & Johnson’s total revenue.

Pharmaceutical

Johnson & Johnson’s Pharmaceutical segment focuses on Immunology, Pulmonary Hypertension, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, and Oncology. The company’s major brands in the Pharmaceutical segment includes:

  • Stelara: used in the treatment of severe plaque psoriasis in children and adults.
  • Remicade: used in the treatment of immune-mediated inflammatory diseases.
  • Risperdal Consta: used in the treatment of schizophrenia and bipolar disorder in adults.
  • Opsumit: used in the treatment of pulmonary arterial hypertension.
  • Invokamet SR: used in the treatment of type 2 diabetes in adults.

Johnson & Johnson’s revenue from the Pharmaceutical segment rose from $10.76 billion in Q4 2019 to $11.95 billion in Q4 2020, a growth of 11.05% on a year-on-year basis. In Q4 2020, the Pharmaceutical segment contributed 55.58% to Johnson & Johnson’s total revenue. 

Company Overview

Johnson & Johnson is an American multinational healthcare company. The company was founded by James Johnson, Edward Johnson, and Robert Johnson in 1886. Johnson & Johnson’s main office is located in New Brunswick, New Jersey, United States. Alex Gorsky is the current Chairman and CEO of the company. Johnson & Johnson employs more than 130,000 people in different parts of the world. The company’s products are available in most parts of the world. Johnson & Johnson’s manufacturing facilities are located in United States, Europe, Africa, Asia, and the Pacific.

Johnson & Johnson faces tough competition from Novartis, Merck, Roche, Boston Scientific, Abbott, Glaxo Smith Kline, Pfizer, and Medtronic. Over the years, Johnson & Johnson has acquired companies like Momenta Pharmaceuticals, Mitek Products, Janssen, 3-Dimensional Pharmaceuticals, Auris Health, Verb Surgical, Taris Biomedical, and many more. These acquisitions have helped the company in increasing its product portfolio and fight competition in the markets. Johnson & Johnson is listed on the NYSE and is traded under the stock code “JNJ”.

Did you like Johnson & Johnson’s Revenue Breakdown statistic?

Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.

You can also get started for free.

Read more

Our Plans

Always know what you’ll pay. No hidden costs or surprises.

  • Annual
  • Monthly

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
$9.9
per month*
Buy Now

51% discount until July 31

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
$19
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Billed annually, local taxes extra. 

Basic

Get to know us

  • Access basic data
  • No credit card required
$0
per month
Start for Free

Investor

The essentials toolkit

  • Financial data & tools Features include : Stock screener, stock comparison, sector data, investor warnings, advanced charting tools, financial statements dating back 10+ years, stock reports, SEC filings and stock ratings. There are 200+ financial items and ratios on thousands of US stocks.
  • Download data Download underlying data in csv and xlsx (Excel) formats for offline analysis.
  • Priority support Fanatical 24*7 customer support to ensure seamless access for you.
$19
per month*
Buy Now

51% discount on Annual plan

Pro

For serious investing

  • All of Investor plan All the features in Investor plan, are included in the Pro plan.
  • Granular data & tools Over 100,000 company-specific key performance indicator statistics. Examples include AT&T's broadband subscriber trends, Tesla's deliveries by model and more. Also, access financials by segment / region / product category etc.
  • Industry data & tools Access data on 40+ industries. For example, datasets include market share, smartphone shipments by vendor, subscribers by wireless carrier, historical gold production. There are 20,000+ such statistics.
$39
per month*
Buy Now

Enterprise

For tailored workflows

  • All of Pro plan Get unfettered access to all our dashboards and dossiers.
  • Custom Dashboards Get tailored dashboards built specially for you, to simplify your research workflow.
  • Bespoke Research We'll expand our granular coverage to companies and sectors of your choice.
$99
per month, onwards*
Contact Us

* Local taxes extra. 

BQ Star 51% off

Get Pro for 51% off

  • Access all features immediately
  • Datasets updated every day
  • Export data in CSV and XLSX formats

Offer Ends In

Starting from $39 $10 / month

.